DOI QR코드

DOI QR Code

Diagnostic Relevance of Overexpressed Serine Threonine Tyrosine Kinase/Novel Oncogene with Kinase Domain (STYK1/NOK) mRNA in Colorectal Cancer

  • Orang, Ayla Valinezhad (Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz) ;
  • Safaralizadeh, Reza (Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz) ;
  • Hosseinpour Feizi, Mohammad Ali (Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz) ;
  • Somi, Mohammad Hossein (Liver and Gastroenterology Diseases Research Center, Tabriz University of Medical Sciences)
  • Published : 2014.08.30

Abstract

Background: Alterations in gene expression levels or mutations of tyrosine kinases are detected in some human cancers. In this study, we examined whether serine threonine tyrosine kinase 1 (STYK1)/novel oncogene with kinase domain (NOK) is overexpressed in patients with colorectal cancer. We also examined the clinical relevance of STYK1/NOK expression in cancer tissues. Materials and Methods: In tumor samples of patients with colorectal cancer and their matched non-cancerous samples, STYK1/NOK messenger RNA (mRNA) expression was analyzed by quantitative reverse transcriptase polymerase chain reaction. Associations between the expression levels of STYK1/NOK and clinicopathological characteristics of colorectal cancer were also assessed using Mann-Whitney U and Kruskal-Wallis tests. Results: Upregulation of STYK1/NOK was found in cancer tissues even at early stage of colorectal cancer compared to normal adjacent tissues. The optimal cutoff point of 0.198 the STYK1/NOK expression showed 0.78 sensitivity and 0.75 specificity for diagnosis. Overexpressed STYK1/NOK was correlated with tumor size but had no association with other clinicopathological characteristics of colorectal cancer. Conclusions: These results indicate that STYK1/NOK mRNA is widely expressed in the patients with colorectal cancer and suggest that inhibition of this molecule could potentially serve as a novel therapeutic target.

Keywords

Colorectal cancer;oncogene;tyrosine kinase;NOK/STYK1;diagnosis

References

  1. Amachika T, Moriai R, Tsuji N, Watanabe N (2007). Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer, 56, 337-40. https://doi.org/10.1016/j.lungcan.2007.01.002
  2. Barouni M, Larizadeh MH, Sabermahani A, Ghaderi H (2012). Markov's modeling for screening strategies for colorectal cancer. Asian Pac J Cancer Prev, 13, 5125-9. https://doi.org/10.7314/APJCP.2012.13.10.5125
  3. Barrett J, Jiwa M, Rose P, Hamilton W (2006). Pathways to the diagnosis of colorectal cancer: an observational study in three UK cities. Fam Pract, 23, 15-9. https://doi.org/10.1093/fampra/cml910
  4. Berclaz G, Andres AC, Albrecht D, et al (1996). Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun, 226, 869-75. https://doi.org/10.1006/bbrc.1996.1442
  5. Blume-Jensen P and Hunter T (2001). Oncogenic kinase signalling. Nature, 411, 355-65. https://doi.org/10.1038/35077225
  6. Chen Y, Li YH, Chen XP, et al (2005). Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res, 65, 10838-46. https://doi.org/10.1158/0008-5472.CAN-05-1091
  7. Chung S, Tamura K, Furihata M, et al (2009). Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci, 100, 2109-14. https://doi.org/10.1111/j.1349-7006.2009.01277.x
  8. Danilkovitch-Miagkova A, Zbar B (2002). Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest, 109, 863-7. https://doi.org/10.1172/JCI0215418
  9. Ding X, Jiang QB, Li R, Chen S, Zhang S (2012). NOK/ STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes. Biochem Biophys Res Commun, 421, 468-73. https://doi.org/10.1016/j.bbrc.2012.04.016
  10. Fambrough D, McClure K, Kazlauskas A, Lander ES (1999). Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell, 97, 727-41. https://doi.org/10.1016/S0092-8674(00)80785-0
  11. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F (1987). A novel putative tyrosine kinase receptor encoded by the eph gene. Science, 238, 1717-20. https://doi.org/10.1126/science.2825356
  12. Hubbard SR and Till JH (2000). Protein tyrosine kinase structure and function. Annu Rev Biochem, 69, 373-98. https://doi.org/10.1146/annurev.biochem.69.1.373
  13. Jackson KA, Handy J, Kimbro KS (2009). Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J Ovarian Res, 2, 15-21. https://doi.org/10.1186/1757-2215-2-15
  14. Karimi K, Mahmoudi T, Karimi N, et al (2013). Is there an association between variants in candidate insulin pathway genes IGF-I, IGFBP-3, INSR, and IRS2 and risk of colorectal cancer in the Iranian population? Asian Pac J Cancer Prev, 14, 5011-6. https://doi.org/10.7314/APJCP.2013.14.9.5011
  15. Kimbro KS, Willard M, Moore JA, Freeman S (2008). A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep, 35, 23-7. https://doi.org/10.1007/s11033-006-9047-1
  16. Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N (2009). Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp Hematol, 37, 824-30. https://doi.org/10.1016/j.exphem.2009.04.010
  17. Kornprat P, Pollheimer MJ, Lindtner RA, et al (2011). Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol, 34, 43-9. https://doi.org/10.1097/COC.0b013e3181cae8dd
  18. Lamorte L and Park M (2001). The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am, 10, 271-88,
  19. Li YH, Wang YY, Zhong S, at al (2009). Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol Cells, 27, 39-45. https://doi.org/10.1007/s10059-009-0003-5
  20. Liu L, Yu XZ, Li TS, et al (2004). A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res, 64, 3491-9. https://doi.org/10.1158/0008-5472.CAN-03-2106
  21. Matsuda Y, Uenda J, Ishiwata T (2012). Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog Res Int, 2012, 574768.
  22. Robinson D, He F, Pretlow T, Kung HJ (1996). A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA, 93, 5958-62. https://doi.org/10.1073/pnas.93.12.5958
  23. Safaee A, Moghimi-Dehkordi B, Fatemi SR, et al (2010). Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev, 11, 1373-5.
  24. Samanian S, Mahjoubi F, Mahjoubi B, Mirzaee R, Azizi R (2011). MDR1 gene polymorphisms: possible association with its expression and clinicopathology characteristics in colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3141-5.
  25. Sato T, Oshima T, Yoshihara K, et al (2009). Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Re, 21, 211-6.
  26. Shemirani AI, Haghighi MM, Zadeh SM, et al (2011). Simplified MSI marker panel for diagnosis of colorectal cancer. Asian Pac J Cancer Prev, 12, 2101-4.
  27. Shepard HM, Brdlik CM, Schreiber H (2008). Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest, 118, 3574-81. https://doi.org/10.1172/JCI36049
  28. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  29. Spano JP, Lagorce C, Atlan D, et al (2005). Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol, 16, 102-8. https://doi.org/10.1093/annonc/mdi006
  30. Zwick E, Bange J, Ullrich A (2002). Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med, 8, 17-23. https://doi.org/10.1016/S1471-4914(01)02217-1

Cited by

  1. Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo vol.37, pp.10, 2016, https://doi.org/10.1007/s13277-016-5188-6
  2. STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma vol.39, pp.7, 2017, https://doi.org/10.1177/1010428317711644
  3. Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1285-y
  4. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel pp.07302312, 2019, https://doi.org/10.1002/jcb.28371